Evidence map›Paper›PMID 29522446›Full record

Trial reportNutrients2018

Sucrosomial Iron Supplementation in Anemic Patients with Celiac Disease Not Tolerating Oral Ferrous Sulfate: A Prospective Study.

Luca Elli, Francesca Ferretti, Federica Branchi, Carolina Tomba, Vincenza Lombardo, Alice Scricciolo, Luisa Doneda, Leda Roncoroni

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Nutrients, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07563582 (Efficacy of Oral Sucrosomial Iron Supplementation in Children With Celiac Disease and Iron Deficiency or Anemia), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07563582 narecruitingnot on this mapstarted 2025, after this paper: background citation

Efficacy of Oral Sucrosomial Iron Supplementation in Children With Celiac Disease and Iron Deficiency or Anemia: a Double-blind, Randomized, Placebo-controlled Trial

TypeinterventionalSponsorIstituto Giannina GasliniRan2025 to 2027Enrolled60ConditionsCeliac Disease in Children, Anemia, Iron DeficienciesArmsSideral forte® VERUM drops, Sideral forte® matching PLACEBO drops
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Comparative evaluation of different oral iron salts in the management of iron deficiency anemia.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2024
    Observational
  7. Review
  8. Article
  9. Pilot Study to Gain First Indications for the Impact of a 3-Month's Oral Intake of a Sucrosomial Iron Supplement on Hemoglobin in Iron-Deficient Blood Donors.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2023
    Article
  10. Article
  11. SucrosomialPharmaceuticals (Basel, Switzerland) · 2023
    Review
  12. Article
  13. Review
  14. Supplementation with Sucrosomial® iron leads to favourable changes in the intestinal microbiome when compared to ferrous sulfate in mice.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2022
    Article
  15. Review
  16. Article
  17. Review
  18. Observational
  19. Iron Therapy in Chronic Kidney Disease: Days of Future Past.International journal of molecular sciences · 2021
    Review
  20. Acquired Refractory Iron Deficiency Anemia.Mediterranean journal of hematology and infectious diseases · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Luca ElliCenter for the Prevention and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. luca.elli@policlinico.mi.it.
Francesca FerrettiDepartment of Pathophysiology and Transplantation, University of Milano, 20100 Milan, Italy. francesca.ferretti@unimi.it.
Federica BranchiDepartment of Pathophysiology and Transplantation, University of Milano, 20100 Milan, Italy. federica.branchi@unimi.it.
Carolina TombaCenter for the Prevention and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. tomba.carolina@gmail.com.
Vincenza LombardoCenter for the Prevention and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. vincenza.lombardo@policlinico.mi.it.
Alice ScriccioloCenter for the Prevention and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. alice.scricciolo@policlinico.mi.it.
Luisa DonedaDepartment of Biomedical, Surgical and Dental Sciences, University of Milano, 20100 Milan, Italy. luisa.doneda@unimi.it.
Leda RoncoroniCenter for the Prevention and Diagnosis of Celiac Disease, Gastroenterology and Endoscopy Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy. leda.roncoroni@tiscali.it.
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITUniversity of Milan · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with celiac disease (CD) frequently suffer from iron deficiency anemia (IDA) and may benefit from iron supplementation. However, intolerance to iron sulfate and duodenal atrophy could reduce the efficacy of this supplementation. This study evaluated the efficacy of a new sucrosomial iron formulation in patients with CD. Consecutive patients with CD and IDA were divided into two groups: patients with a known intolerance to iron sulfate were treated with sucrosomial iron (30 mg of iron/day), while those receiving iron supplementation for the first time were assigned to iron sulfate (105 mg of iron/day). Forty-three patients were enrolled (38 females, mean age 49 ± 9 years). After a follow-up of 90 days both groups showed an increase in Hb levels compared to baseline (+10.1% and +16.2% for sucrosomial and sulfate groups, respectively), and a significant improvement in all iron parameters, with no statistical difference between the two groups. Patients treated with sucrosomial iron reported a lower severity of abdominal symptoms, such as abdominal and epigastric pain, abdominal bloating, and constipation, and a higher increase in general well-being (+33% vs. +21%) compared to the iron sulfate group. Sucrosomial iron can be effective in providing iron supplementation in difficult-to-treat populations, such as patients with CD, IDA, and known intolerance to iron sulfate.

Indexed as

Drug CompoundingAdultAnemia, Iron-DeficiencyCeliac DiseaseFemaleHumansIron CompoundsMaleMiddle AgedProspective StudiesIron Compoundsceliac diseaseiron deficiency anemiairon sulfatesucrosomial iron

Identifiers

PMID29522446
PMCPMC5872748
OpenAlexW2789351758

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.